Bemotrizinol gains FDA approval

Bemotrizinol gains FDA approval

On 9 June 2026, the US FDA approved this UV active for use in sunscreen formulations at a maximum permitted level of 6% w/w. READ MORE.

Table of Contents

Other Articles

European Commission & IFRA Updates
Due to concerns about endocrine disruption, this material has, as of 1 May 2026, been banned in the EU and will be banned by the UK in January 2027. It is also currently under review by the TGA. READ MORE.
Changes to New Zealand Cosmetic Products Group Standard

A note from the ASCC Technical Committee

Bemotrizinol (Bis-Ethylhexyloxyphenol Methoxyphenyl Triazine, or BEMT, CAS No. 187393-00-6) is a broad spectrum sunscreen active with absorbance in the UVA (343nm) and UVB (310nm) regions.

On 9 June 2026, the US FDA approved this UV active for use in sunscreen formulations at a maximum permitted level of 6% w/w. It is also recognised by the FDA as GRASE (Generally Regarded as Safe and Effective.) It is the first UV active to be approved by the FDA since 1999.

Formulators and marketers may now include this material in sunscreen products intended to be marketed in the USA.

It is currently approved in Australia at 6% w/w.